Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

NCT04021108 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Gastroesophageal Adenocarcinoma

Interventions

DRUG: Nivolumab 240 MG

Sponsor

Weill Medical College of Cornell University

Collaborators

[object Object]